

10/532373 Page 1 of 1

**FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT**

SERIAL NO.	To be assigned
FILING DATE	Concurrently herewith
APPLICANT	Desmond John BEST
GROUP	1625
EXAMINER	ZW DAVIS
ATTORNEY DOCKET NO.	P33128USw

**U.S. PATENT DOCUMENTS**

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page

**FOREIGN PATENT DOCUMENTS**

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
1.	WO02076925	10/3/2002	PCT			
2.	WO0224695	3/28/2002	PCT			
3.	WO0212190	2/14/2002	PCT			
4.	WO0006254	2/10/2000	PCT			
5.	WO0123374	4/5/2001	PCT			
6.	WO01066520	9/13/2001	PCT			
7.	WO02094788	11/28/2002	PCT			
8.	WO9850363	11/12/1998	PCT			
9.	WO9850364	11/12/1998	PCT			
10.	WO9840385	9/17/1998	PCT			
11.	WO0166534	9/13/2001	PCT			
12.	WO9534540	12/21/1995	PCT			

Continue on page

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

13.	ADCOCK et al., "Substituent Effects of <sup>19</sup> F Nuclear Magnetic Resonance: Polar and π-Electron Effects", Aust. J. Chem 29:2571-2581 (1976).
14.	AUSTIN et al., "Novel 2,3,4,5-Tetrahydro-1H-3-benzazepines with High Affinity and Selectivity for the Dopamine <sub>3</sub> Receptor", Bioorg Med Chem Lett 10:2553-2555 (2000).
15.	AUSTIN et al., "Design and Synthesis of Novel 2,3-Dihydro-1H-isoindoles with High Affinity and Selectivity for the Dopamine D <sub>3</sub> Receptor," Bioorg Med Chem Lett 11:685-688 (2001).
16.	FRANKEL, Chemische Berichte Vol. 33 pp. 2811 (1900).
17.	GIOVANNINI et al., "Effects of histamine H <sub>3</sub> receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," Behavirual Brain Res. 104:147-155 (1999).
18.	LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," TiPS 19:177-183 (May 1998).
19.	LOVENBERG et al., "Cloning and Funcational Expression of the Human Histamine H <sub>3</sub> Receptor," Molecular Pharmacology 55:1101-1107 (1999).
20.	ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).
21.	RICE et al., "Synthesis of Fluorinated Derivatives of Benzo[k]fluoranthene and indeno[1,2,3-cd]pyrene and 8,9-Dihydro-8,9-epoxybenzo[k]fluoranthene," J. Org. Chem 53:1775-1779 (1988).
22.	SCHLICKER et al., "Modulation of neurotransmitter release via histamine H <sub>3</sub> heteroreceptors," Fundam Clin Pharmacol 8:128-137 (1994).
23.	STOKKER, "Preparation of 1,2,3,4-Tetrahydroisoquinolines Lacking Electron Donating Groups – An Intramolecular Cyclization Complementary to the Pictet-Spengler Reaction," Tetrahedron Letters 37(31):5453-5456 (1996).
24.	WALSH et al., "Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and Structurally Related Compounds," J. Med. Chem 32:105-118 (1989).
25.	WEINSTOCK et al., "Synthesis and Renal Vasodilator Activity of Some Dopamine Agonist 1-Aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: Halogen and Methyl Analogues of Fenoldopam," J. Med. Chem 29:2315-2325 (1986).

Continue on page

EXAMINER	<i>Zenna N Davis</i>	DATE CONSIDERED
		12/31/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10532373
	Filing Date		2005-04-21
	First Named Inventor		Best
	Art Unit		4614- 1625
	Examiner Name		(not yet assigned) ZNDAVS
	Attorney Docket Number		P33128USw

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
<i>Znd</i>	1	9221476	JP		1997-08-26	Otsuka Pharmaceutical Co. Ltd.	(Abstract only)	<input checked="" type="checkbox"/>
<i>Znd</i>	2	2004035544	WO	A1	2004-04-29	Glaxo Group Ltd.		<input type="checkbox"/>
<i>Znd</i>	3	2004035556	WO	A1	2004-04-29	Glaxo Group Ltd.		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Not for submission under 37 CFR 1.99)</i>		Application Number		10532373	
		Filing Date		2005-04-21	
		First Named Inventor		Best	
		Art Unit		1625	
		Examiner Name		(not yet assigned) ZNDAVIS	
		Attorney Docket Number		P33128USw	

<i>mpk</i>	4	2004037800	WO	A1	2004-05-06	Glaxo Group Ltd.	<input type="checkbox"/>
<i>mpk</i>	5	1262475	EP	A1	2002-12-04	Ono Pharmaceutical Co., Ltd.	<input type="checkbox"/>
<i>mpk</i>	6	2004026305	WO	A1	2004-04-01	Eli Lilly & Company	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature *Zinn W Davis* Date Considered *12/31/2007*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.